Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection
Journal of Hepato-Biliary-Pancreatic Sciences · 2023-06 · 30 (6) · 815-824
DOI: 10.1002/jhbp.1282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2022-12. Verfasst von Tatsuo Hata und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC), Japan Society for the Promotion of Science (JSPS) KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Purpose
We aimed to clarify the prognostic impact of postoperative circulating tumor DNA (ctDNA) shortly after pancreatectomy in patients with pancreatic ductal adenocarcinoma (PDAC).
Methods
Preoperative and paired postoperative blood samples were obtained from 66 patients in patients with PDAC. Cell‐free DNA was extracted from the plasma, and KRAS mutations, as a benchmark of ctDNA, were examined using droplet digital PCR. Disease‐free survival (DFS) and overall survival (OS) were compared between patients with presence and absence of ctDNA.
Results
In univariate analysis, patients with detectable postoperative ctDNA showed worse survival than those with undetectable in both DFS ( P = .034) and OS ( P = .022). Multivariate analysis also revealed that the presence of postoperative ctDNA was an independent risk factor for recurrence (hazard ratio: 2.677, P = .011). In contrast, preoperative ctDNA detection did not affect long‐term outcomes. These trends persisted in 34 patients with resectable PDAC who underwent resection after neoadjuvant chemotherapy. Patients with detectable postoperative ctDNA were more prone to developing hepatic recurrence than those with undetectable postoperative ctDNA ( P = .039).
Conclusion
Postoperative ctDNA, as a minimal residual marker, can be useful for predicting the risk of recurrence in patients with PDAC even after curative resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Surgery I, Yamagata University Graduate School of Medical Science, Yamagata, Japan.
ORCID-Profile: Tatsuo Hata, Masamichi Mizuma, Fuyuhiko Motoi, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Michiaki Unno
Förderung
- Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC)
- Japan Society for the Promotion of Science (JSPS) KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Hata, T., Mizuma, M., Motoi, F., Ohtsuka, H., Nakagawa, K., Morikawa, T., & Unno, M. (2023). Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection. Journal of Hepato-Biliary-Pancreatic Sciences, 30(6), 815-824. https://doi.org/10.1002/jhbp.1282
Vancouver
Hata T, Mizuma M, Motoi F, Ohtsuka H, Nakagawa K, Morikawa T, et al. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection. Journal of Hepato-Biliary-Pancreatic Sciences. 2023;30(6):815-824. doi:10.1002/jhbp.1282
BibTeX
@article{Hata2023,
author = {Hata, Tatsuo and Mizuma, Masamichi and Motoi, Fuyuhiko and Ohtsuka, Hideo and Nakagawa, Kei and Morikawa, Takanori and Unno, Michiaki},
title = {Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2023},
volume = {30},
number = {6},
pages = {815--824},
doi = {10.1002/jhbp.1282}
}
EUVIMED